https://scholars.lib.ntu.edu.tw/handle/123456789/503575
標題: | Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy | 作者: | WANG-HUEI SHENG JIA-HORNG KAO PEI-JER CHEN LI-MIN HUANG SUI-YUAN CHANG HSIN-YUN SUN CHIEN-CHING HUNG Chen M.-Y. SHAN-CHWEN CHANG |
公開日期: | 2007 | 卷: | 45 | 期: | 9 | 起(迄)頁: | 1221-1229 | 來源出版物: | Clinical Infectious Diseases | 摘要: | Background. Evolution of serological markers of hepatitis B virus (HBV) carriage or infection has rarely been investigated among human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART). Methods. During the period 1997-2002, a total of 633 HIV-infected patients were tested for HBV serological markers at baseline, including hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs ), antibody to hepatitis B core antigen (anti-HBc), hepatitis C virus (HCV) antibody (anti-HCV) antibody, HCV RNA level, and HBV DNA level, all of which were retested at least 1 year apart. Medical records were reviewed to identify clinical characteristics associated with evolution of these serological markers. Results. After a median duration of follow-up for 4.96 years, 161 patients (25.4%) had changes in HBV serological markers. Of 119 patients (18.8%) who tested positive for HBsAg at baseline, 6 (5.0%) developed anti-HBs, and 9 (7.6%) developed isolated anti-HBc. Of 270 patients (42.7%) who tested positive for anti-HBs, 18 (6.7%) lost anti-HBs. Of 179 patients (28.3%) in whom isolated anti-HBc had been detected, 73 (40.8%) developed anti-HBs, 18 (10.1%) lost all HBV markers, and 7 (3.9%) developed HBsAg. Of 65 patients (10.2%) who tested negative for all HBV markers, 13 (20%) developed anti-HBs, 13 (20%) developed isolated anti-HBc, and 4 (6.2%) developed HBsAg, indicating a high risk of HBV exposure. Patients in whom anti-HBc was detected at baseline were more likely to have acquired immunodeficiency syndrome (P = .008). Multivariate analysis revealed that an increase in the CD4 cell count after the commencement of HAART was significantly associated with persistence or subsequent development of anti-HBs in patients with anti-HBs or anti-HBc at baseline, respectively. Conclusions. Periodic measurements of HBV serological markers in HIV-infected patients are recommended, because new HBV infections and changes of HBV serological markers are not uncommon in patients with improved immunity after commencement of HAART. ? 2007 by the Infectious Diseases Society of America. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/503575 | ISSN: | 1058-4838 | DOI: | 10.1086/522173 | SDG/關鍵字: | antiretrovirus agent; hepatitis B core antibody; hepatitis B surface antibody; hepatitis B surface antigen; hepatitis C antibody; acquired immune deficiency syndrome; adult; aged; article; CD4 lymphocyte count; controlled study; female; follow up; hepatitis B; Hepatitis B virus; Hepatitis C virus; highly active antiretroviral therapy; human; Human immunodeficiency virus infection; major clinical study; male; medical record review; multivariate analysis; priority journal; serology |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。